Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 906 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Saline Infusion Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of CDX-0159

NCT04146129
View directory record Official record
Conditions
Healthy Subjects
Interventions
CDX-0159, Normal saline
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers

NCT05642546
View directory record Official record
Conditions
Healthy
Interventions
NM8074, Placebo
Drug
Lead sponsor
NovelMed Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Phase 4 Interventional Results available

Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

NCT05822583
View directory record Official record
Conditions
COVID-19
Interventions
abatacept infusion, Placebo group
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
82
States / cities
Birmingham, Alabama • Tucson, Arizona • Davis, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sleep and Healthy Aging Research on Depression for Younger Women

NCT03848715
View directory record Official record
Conditions
Anhedonia, Depression
Interventions
Endotoxin, Placebo
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
25 Years to 44 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 13, 2026, 2:06 AM EDT
Suspended Phase 3 Interventional Accepts healthy volunteers

The Effects of Sex Hormones and Alcohol on Sleep

NCT06143059
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Ethanol, Saline
Drug
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 45 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Phase 4 Interventional Results available

Treating Phantom Limb Pain Using Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study

NCT01824082
View directory record Official record
Conditions
Phantom Limb Pain
Interventions
Perineural infusion [continuous peripheral nerve block(s)]
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Palo Alto, California • San Diego, California • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

NCT05717062
View directory record Official record
Conditions
Snakebite, Envenoming, Snake
Interventions
Varespladib intravenous form, varespladib-methyl- oral form, Placebo intravenous form, Placebo - oral form
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Berinert (C1INH) vs Placebo for DGF/IRI

NCT04696146
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Diseases
Interventions
Berinert, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 13, 2026, 2:06 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

NCT07810946
View directory record Official record
Conditions
Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions
Sodium Acetate, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

NCT01258608
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Mapatumumab, Placebo, Sorafenib
Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
9
States / cities
Aurora, Colorado • Shreveport, Louisiana • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial

NCT00100178
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Mycophenolate mofeteil (MMF), Daclizumab (DZB), Placebo control for Mycophenolate mofeteil (MMF), Placebo control for Daclizumab (DZB)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery

NCT05027048
View directory record Official record
Conditions
Uterine Atony, Uterine Atony With Hemorrhage, Postpartum Hemorrhage, Cesarean Section Complications
Interventions
Calcium chloride, Saline placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pacifica, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 13, 2026, 2:06 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury

NCT06825143
View directory record Official record
Conditions
Metabolic Syndrome, Vascular Injury, Ischemic Preconditioning, Endothelial Function (reactive Hyperemia), Endothelial Dysfunction
Interventions
Ischemic preconditioning, Intravenous lactate infusion, No ischemic preconditioning (control), Normal Saline Infusion (Placebo), Ischemic preconditioning and intravenous lactate
Procedure · Drug · Combination Product
Lead sponsor
Gary Van Guilder
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Gunnison, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Early Phase 1 Interventional Results available

Ketamine Infusion for Social Anxiety Disorder

NCT02083926
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Ketamine, Saline
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

Early Blood Pressure Management in Extremely Premature Infants

NCT00874393
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Hypotension, Blood Pressure
Interventions
Dopamine, Hydrocortisone, Infusion Placebo, Syringe Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 24 Hours
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271

NCT02724085
View directory record Official record
Conditions
Pneumonia
Interventions
TP-271
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Early Phase 1 Interventional

Angiotensin-(1-7) and Energy Expenditure in Human Obesity

NCT03777215
View directory record Official record
Conditions
Obesity
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Amy Arnold
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 13, 2026, 2:06 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation

NCT00608231
View directory record Official record
Conditions
Parkinson's Disease, Essential Tremor, Dystonia
Interventions
Dexmedetomidine Hydrochloride Infusion, Normal Saline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Phase 1 Interventional

GLP 1 for Intraoperative Glycemic Control

NCT00882492
View directory record Official record
Conditions
Hyperglycemia, Hypoglycemia
Interventions
GLP 1, normal saline solution placebo
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome

NCT05682560
View directory record Official record
Conditions
Long COVID, Post-COVID Syndrome, Post COVID-19 Condition
Interventions
REGENECYTE, Placebo
Biological
Lead sponsor
StemCyte, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 13, 2026, 2:06 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

New Formulations of Propafenone to Treat Atrial Fibrillation

NCT02710669
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
(R)-propafenone, (S)-Propafenone, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 13, 2026, 2:06 AM EDT
Terminated Phase 1 Interventional

An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome

NCT02562820
View directory record Official record
Conditions
Rett Syndrome
Interventions
Intravenous infusion
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
5 Years to 25 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Tolerability Study of RJX Drug Product in Healthy Participants

NCT03680105
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
RJX, Placebo
Drug
Lead sponsor
Reven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 13, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

NCT05953480
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Redasemtide, Placebo
Biological · Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
17
States / cities
Tucson, Arizona • Sarasota, Florida • Augusta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 13, 2026, 2:06 AM EDT